About
Michael Curtis, Ph.D., is President and CEO of eGenesis, a clinical-stage biotechnology company developing gene-edited organs for transplantation. Before becoming CEO in 2022, he joined eGenesis in 2020 as President of Research & Development after serving as President and Head of R&D at Cadent Therapeutics. His career has focused on biopharmaceutical R&D, including prior leadership roles at Catabasis Pharmaceuticals and Infinity Pharmaceuticals.
Areas of interest
biotechxenotransplantationgenome engineeringorgan transplantationkidney diseaseliver diseaseneurosciencerare diseaseoncology